Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P‐glycoprotein

Background & Aims Cabozantinib, a small‐molecule multitargeted tyrosine kinase inhibitor, has entered into a phase III clinical trial for the treatment of hepatocellular carcinoma ( HCC ). This study assessed the mechanistic effect of cabozantinib on the reversal of P‐glycoprotein (P‐gp)‐mediated multidrug resistance ( MDR ). Methods CCK ‐8 assays and tumour xenografts were used to investigate the reversal of MDR in vitro and in vivo...